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ABSTRACT 
OBJECTIVE 
To study the accuracy, sensitivity and specificity of Colour Doppler in 
differentiating Benign and Malignant ovarian tumours in 15-60 yrs age group 
patients attending Gynaecology Clinic at Government Kilpauk Medical College 
Hospital, Chennai. 
STUDY DESIGN: 
A Prospective observational study between January 2012 to September 2013 at 
Kilpauk Medical College Hospital, Chennai. 
METHODS: 
Women  attending gynaecology clinic from 15-60yrs, who diagnosed to have 
significant adnexal mass are selected. All diagnostic modalities done including 
ultrasonography,ca125,colour Doppler calculating resistive and pulsality index 
are done. Finally results are compared with Histopathology 
RESULTS: 
75 patients  are recruited .out of 75 patients, 15 are malignant and 60 are benign. 
Ultrasonography has sensitivity and specificity 66.7% and 81% respectively 
CT Abdomen and pelvis has sensitivity and specificity of 80% and 85% 
respectively 
Ca125 has sensitivity and specificity of 66.67% and 83.3% respectively 
Sensitivity  and specificity of resistive index is93.3% and 86.7% respectively 
Area under curve is 0.922 which is statistically significant p value-<0.0001. 
With the PI of 0.9 the sensitivity and specificity is 86.7% and 93.3% 
respectively.With Receiver operative curve 
Area under curve is 0.925  which is statistically significant p value<0.0001 
Thus colour Doppler with high accuracy helps in early diagnosis for prompt 
traerment. 
  CONCLUSION: 
Thus colour Doppler have high accuracy in differentiating benign and malignant 
ovarian tumours. 
KEY WORDS: 
Ovarian tumours  Diagnosis, Resistive index, Pulsality  index, Colour Doppler, 
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INTRODUCTION 
 
Ovarian cancer is a cancerous growth arising from the ovary.It is 
three times more dangerous than the breast cancer.Ovarian cancer is 
characterized by few early symptoms and it presents  usually in an advanced 
stage with a poor survival rate.The high mortality rate is due to the 
difficulties in early detection of ovarian cancer. Around 80% of patients are 
diagnosed in the advanced stage of the disease.  
In patients who are diagnosed in early stages (stage I or II), the 5-year 
survival ranges  from 60% to 90%, depending on the degree of tumor 
differentiation.Poor prognosis of the disease is due to late diagnosis 3. 
          Preoperative diagnosis of ovarian cancer as benign or malignant may 
help the gynecologist in planning the mode of treatment. Recently the role 
of Colour Doppler Ultrasonography in the diagnosis of ovarian malignancy 
has been a subject of discussion.6 ,7 
A  more recent development for diagnosing the malignant ovarian 
mass is the Colour Doppler Ultrasonography(CDS). It identifies low 
resistance flow in intra-tumoral blood vessels, which is secondary to 
angiogenesis and neovascularization in malignant tumors5.  
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This has been further discussed by several researches done by 
 Bourne et al., 1989; Kurjak et al., 1993;     Rieck et al., 2006; 
 Fleischer &Andreotti, 2005).12,23,25. 
 
By knowing the blood flow characteristics, one can predict whether 
the tumor is benign or malignant. Researchers have proposed Colour and 
Pulsed Doppler flow imaging as methods that may be useful in 
differentiating benign from malignant ovarian masses. According to the 
study based on ”Folkman theory of neovascularisation”, malignant 
neoplasms elaborate a factor called Tumour angiogenesis factor, which 
stimulates rapid formation of new capillaries5. 
          I have chosen this topic because of the alarming increase in the 
incidence of malignant ovarian tumors in the last 20 years and ovarian 
malignancy is becoming an important cause of death in gynaeconcology.34 
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REVIEW OF LITERATURE 
This is discussed under the following headings: 
 INCIDENCE 
 ANATOMY 
 HISTOLOGY 
 EMBRYOLOGY 
 RISK FACTORS 
 CLASSIFICATION OF OVARIAN TUMOURS 
  HISTOLOGICAL TYPES OF EACH OVARIAN TUMOURS 
 INCIDENCE 
 MORPHOLOGY 
 HISTOLOGY 
 
 DIAGNOSIS  
 ULTRASONOGRAPHY 
 CT ABDOMEN AND PELVIS 
 CA125 
 COLOUR DOPPLER ULTRASONOGRAPHY 
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INCIDENCE 
The American Cancer Society estimates for ovarian cancer in the 
United States for 2013 are: 
About 22,240 women will receive a new diagnosis of ovarian cancer. 
About 14,230 women will die from ovarian cancer. 
Ovarian cancer  ranks fifth in cancer deaths among women, 
accounting for more deaths than any other cancer of the female reproductive 
system. Ovarian cancer accounts for about 3% of all cancers in women.A 
woman's risk of getting ovarian cancer during her lifetime is about 1 in 
72.Her lifetime chance of dying from ovarian cancer is about 1 in 100.The 
mean age at diagnosis is 63 yrs or older. 
The incidence of ovarian cancer varies between the regions with the 
highest rates noted in Europe and North America. According to SEER 
cancer statistics rule published in June 2013 the number of new cases of 
ovarian tumour was 12.5 per 100,000 women per year. Incidence in Five 
Continents for various Indian registries found that during the period     
2001-06, the age-standardized incidence rates (ASR) for ovarian cancer 
varied from 0.9 to 8.4 per 100,000 person years amongst various registries. 
Incidence of ovarian tumour in Asia is 5.1.   In India the highest incidence 
noted in Pune and Delhi registries. 
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MAP SHOWING  DEATH DUE TO OVARIAN CANCER 
  
Worldwide distribution 
 
 
 
 
 
High mortality     Low mortality 
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ANATOMY 
 
 
Ovaries are oval in shape and pinkish grey in colour. Each measures about 
5cm in length,3cm in breadth and 3cm in thickness. 
 
 
 
 
 
 
 
            
 Figure: 1 shows the relationship of the ovary 
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OVARIAN FOSSA 
Ovaries lies in ovarian fossa in lateral pelvic wall. It is related to 
external  iliac vein superiorly, ureter and internal iliac vein posteriorly, 
peritoneum separating obturator vessels laterally. 
HISTOLOGY 
 Ovary is lined by a single layer of cuboidal epithelium known as 
germinal epithelium. Substance of the gland consists of outer cortex and 
inner medulla. 
CORTEX: 
 It consists of stromal cells which are thickened beneath the germinal 
epitheliu to form tunica albuginea.  
 
 
 
 
 
Figure 2:Histology of ovary 
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MEDULLA: 
 It consists of loose connective tissues,blood vessels and nerves.There 
are small collection of cells called hilus cells,which are homologous to the 
interstitial cells of testes. 
EMBRYOLOGY 
 After 5th week of fertilization, two gonadal ridges develop on either 
side of the midline in the dorsal aspect of the embryo. These are formed by 
the proliferation of coelomic epithelium. The primodial germ cells are 
formed in the yolk sac and migrate along the mesentery of the hindgut  into 
these gonadal ridges. These gonadal swelling differentiate into ovary or 
testis depending on the sex chromosome. 
 
 
 
 
 
 
 
Figure 3 a:shows  migration of primodial germ cells 
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BLOOD SUPPLY: 
           Arterial supply is from the ovarian artery, a branch of the abdominal 
aorta.Venous drainage is through the pampiniform plexus, which drain into 
inferior vena cava on right side and left renal vein on left side. 
NERVE SUPPLY: 
              Sympathetic supply is from T10 segment, through the renal and 
aortic plexus. 
 
PROTECTIVE FACTORS FOR OVARIAN TUMOURS: 
 
Protective factors are oral contraceptive pills as described by (Jensen 
A, Frederickson K), Breast feeding (yen 2003), Retinoid, tubal sterilization 
(Hankinson 1793) and hysterectomy. Women who used oral contraception 
for 5 yrs or more have 50% reduction in the development of ovarian cancer. 
Prophylactic oopherectomy can be done in patients with high risk of ovarian 
cancer >35yrs14. It decreases the risk up to 90%. 
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RISK FACTORS 
It occurs in age group of 56-60yrs. In postmenopausal women, 30% 
are malignant, but in premenopausal women only 7% are  malignant.Peak 
age for borderline tumours is 46 yrs. Hereditary ovarian tumours occur 10 
yrs earlier than sporadic tumours. 
Risk factors of ovarian tumor include  
 
 Infertility (Purdie 2003) 
 Low parity(Hinkula 2006) 
 Early menarche 
 Late menopause(lancey 2006) 
 Failure to lactate  
 Smoking 
 Obesity 
 Lack of exercise 
 Talc on the perineum(ness 2000) 
 History of endometriosis 3 
 Ovulation induction 
 Diet rich in fat 
 Familial factors 
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         It has been estimated that life style contribute to 21% of ovarian 
cancer.35,37It is estimated that 2% of cases may be caused by smoking.36; 
38.This is also described by some researchers like Lurie G, Thompson PJ et al 
in 2013. 
         There is also evidence of increased risk in postmenopausal women 
who are overweight and who using dietary products as described by Faber 
MT, Hogdall C study in Danish (2012) 
Parity is inversely related to the incidence of ovarian cancer, having 
at least one child is protective with the reduction risk of 0.3-0.4%. 
Diet rich in animal fat and Ovulation Induction causing incessant 
ovulation has also been studied to be risk factors for ovarian cancer. 
Familial patterns contribute to 5-10% of the ovarian tumours.8 
          Most tumors are associated with germ line mutations in BRCA1 
mutation, smaller proportion by BRCA2 mutation. It follows autosomal 
dominant pattern of inheritance4. Family history of ovarian, breast, colon 
and endometrial cancer increases the risk of ovarian cancer.   Having very 
close relatives  with either ovarian cancer or breast cancer have 3-4 fold 
increase in developing ovarian cancer than  any other women in the 
population.9  
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CLASSIFICATION OF OVARIAN TUMOURS 
3 Main Tumours discussed in study are Epithelial  tumour,Germ cell 
tumour,Sex cord stromal tumours. 
 
EPITHELIAL OVARIAN TUMOURS 
Approximately 90% of ovarian cancers are derived from tissues that 
come from the coelomic epithelium or mesothelium. About 70-80% of the 
ovarian tumours is of serous type. Overall, five-year survival in ovarian 
epithelial carcinoma is 35%.33 
 
Classification by Histologic Type  
 Serous -Endosalpingeal[70-80%] 
 Mucinous –Endocervical[5] 
 Endometrioid–Endometrial[10%] 
 Clear-cell “mesonephroid” [5%] 
 Brenner Transitional[<1%] 
 Mixed epithelial  
 Undifferentiated Anaplastic 
 Unclassified Mesothelioma 
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TUMOURS OF SURFACE  EPITHELIUM 
SEROUS TUMOUR 
INCIDENCE: 
 Serous cystadenoma is common in age group of 30-50yrs. Malignant 
cystadenocarcinoma occur most often in advancing age >50yrs. In Bilateral 
presentation  of the tumour 20% is benign where  as  66% are malignant. 
MORPHOLOGY: 
Surfaces and loculi of the benign cyst contains papillary excrescences 
.In case of malignancy, coarse papillary growth is seen on the peritoneal 
surfaces. Papillae will be friable in malignant tumor.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dddddf  
 
figure 4a:shows cut section of benign serous tumour with friable papillary 
excrescenses  
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Figure 4b &4c:shows papillary excrescences  in malignant serous tumour 
HISTOLOGY: 
 Benign cyst shows cystic spaces and is lined by tall columnar ciliated 
epithelium which resembles endosalpinx. Loculi contains serous straw 
coloured fluid. Psammoma bodies are seen frequently in this tumour. In 
malignant  serous tumours there is increased complexity of papillae, 
stratification, increased nuclear atypia and stromal invasion. Fluid is often 
blood stained.  
 
Figure:5a shows benign serous cystadenoma                             Figure 5 b : shows malignant serous       
                                                                                                  cystadenocarcinoma 
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MUCINOUS TUMOUR 
INCIDENCE: 
           Mucinous tumour constitute   8-10% of epithelial  tumours. They are 
multiloculated cysts. It can grow to a larger size and is usually unilateral. In 
5 % cases it is bilateral. Tumours are usually benign constitute to 80% and 
malignancy in 5-10% cases.Thesetumours are usually associated with 
Brenner  and dermoid cyst. Bilateral tumours often arises from metastasis 
from either mucocele of appendix and primary adenocarcinoma of 
appendix. 
MORPHOLOGY: 
    Tumours are often multilocular, they have glistening surfaces. Cut section 
shows multiloculi, rich in mucin and have honey combed appearance. 
Figure 6 a&b :gross appearance and cut section of mucinous tumour 
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HISTOLOGY: 
 Mucinous cyst is lined by tall columnar epithelium, with vacuolated 
cells with apical mucin. Lining epithelium is endocervical type. 
 
 
 
 
 
 
 
Figure 6c: shows histology of mucinous tumour 
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ENDOMETRIOD TUMOUR 
INCIDENCE: 
 These tumours are mostly malignant, it accounts for 20% of all 
ovarian cancers, and 8-10% of epithelial ovarian tumours. It coexists in 15 
% of cases with ovarian endometriosis.They are associated with endometrial 
carcinoma in 20% of cases. 
MORPHOLOGY: 
 Tumours are solid, with cystic areas  in between,  often filled with 
haemorrhagic fluid. 
HISTOLOGY: 
 They are lined by glandular epithelium resembles endometrium. 
 
 
 
 
 
Figure7: Shows histology of endometriod tumour 
 
 
 
18 
 
CLEAR CELL TUMOUR 
INCIDENCE: 
 About 5% of  epithelial ovarian tumours are clear cell tumours. 
MORPHOLOGY: 
 Tumor is highly malignant. Otherwise called mesonephroid tumour.  
 
HISTOLOGY: 
 Histological types are Solid, Tubulocystic, Reticular  and Papillary.  
The tumour contains clear cells that project the  nuclei into apical cytoplasm 
with hobnail appearance. Focal areas of endometriosis is common. 
 
 
 
 
 
Figure 8:shows histology of clear cell carcinoma with hobnail cells 
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BRENNER TUMOUR 
INCIDENCE: 
 It is a fibro-epithelial solid tumour constituting about 1-2% of total 
ovarian tumour. It may be associated with ascitis and hydrothorax called 
pseudomeig’s syndrome. Rarely it becomes malignant. It occurs in 
postmenopausal women. This tumour is mostly unilateral, mostly benign. 
They have no endocrine function. 
Hookup: 
 It resembles fibroma of the ovary. Cut surface shows gritty and 
yellowish grey colour. 
 
 
 
 
 
 
 
  
 
 
20 
 
HISTOLOGY: 
The tumour shows background of fibrous tissue with nests of 
transitional epithelium (walthard cell nests) interspersed within it. These 
cells may demonstrate a longitudinal groove which resembles puffed wheat 
appearance. Nucleus resemble coffee bean appearance so called coffee bean 
nucleus. 
 
Figure 9a :histology of Brenner tumour   Figure 9 b :histology of Brenner which shows 
with walthard cell nests      grooves 
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GERM CELL TUMOURS 
Germ cell tumours contribute for 15-20%of all ovarian tumours 
Histologic Typing of Ovarian Germ Cell Tumors  
1. Primitive germ cell tumor 
 Dysgerminoma tumors  
 Yolk sac tumor  
 Embryonal carcinoma  
 Polyembryoma 
 Non-gestational choriocarcinoma 
 Mixed germ cell tumor  
 
2. Biphasic or Triphasic teratoma 
 Immature teratoma 
 Mature teratoma 
 Solid  
 Cystic  
 Dermoid cyst 
 Fetiform teratoma 
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3.Monodermal teratoma 
 Thyroidtumour  [Strumaovarii]] 
 Benign 
 Malignant 
 Carcinoid 
 Neuroendocrinetumour 
 Carcinoma 
 Melanocytic 
 Sarcoma 
 Sebaceoustumour 
 Pituitarytumour 
 
 
INCIDENCE OF GERM CELL TUMOUR: 
 95.5% of tumours shows benign cystic teratoma,60% of germ cell 
tumours are below the age of 20 yrs (scully RE et al, 1998)..They arise from  
totipotentcells capable of producing ectodermal,mesodermal,endodermal 
components. 
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DERMOID  
 Dermoid  contribute to about 5-10% of all cystic tumoursDermoid 
cysts are bilateral in 12-15% cases.Simple cyst have maximum incidence at 
the age of 40-50 years.Combined tumours arise in patients between the ages  
of 20-30 years. Epidermoid carcinoma occur in 1.7% of dermoid cyst. 
CYSTIC TUMOURS: 
 It is unilocular  with smooth surface.It contains sebaceous 
material,hair,teeth,bone,cartilage,thyroid tissue and bronchial  mucous 
membrane.Some times these sebaceous material collects together in the 
form of small balls,the inner surface is called a ‘focus’ or embryonic node 
from which the hair project. 
         
 
 
 
 
Figure 10 a :shows histology of dermoid cyst 
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SOLID TUMOURS: 
  They are mostly solid.Cut surface shows peculiar trabecular 
appearance. Solid part of tumour contains cartilage, bone, muscle, glia, 
piamater, intestinal mucous membrane, while hair and sebaceous material 
are found in cystic spaces. Extraovarian dermoid cyst arise from lumbar 
region, uterovesical area, parasacral region and rectovaginal septum. 
 
DYSGERMINOMA 
 It corresponds to seminoma of testis.Itaccounts for 3-5% of all 
ovarian tumours. It usually occurs in young women with the average 
incidence of 20 years.Thetumour is solid with elastic rubbery consistency 
and with smooth, firm capsule.  
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 The cut surface  is yellow,with areas of degeneration and 
haemorrhage. It is often unilateral. It may be bilateral in 10% cases.This 
tumour is highly radiosensitive.The malignancy rate is 30-50%.  
 
 
 
     
 
 
 
 
Figure 11 a:shows cut section of tumour with haemorrhage 
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HISTOLOGY 
Lymphocytes and giant cells are found among the 
tumourcells.Lymphocytic infiltration of the fibrous septa along with large 
dark-staining nuclei with clear translucent cytoplasm are diagnostic features.  
The tumours are neutral and doesnot secrete hormones but secrete placental 
alkaline phosphatase,lactate dehydrogenase and BetaHCG. 
                                                               
 
 
 
 
 
 
 
 
figure 11b : Histology of dysgerminoma with lymphocyte infiltrate with fibrous 
strands 
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YOLK SAC TUMOURS 
Endodermal sinus tumour arise from primitive yolk sac.It is often 
unilateral.Most cells secrete AFP  and alpha 1 antitrypsin.The tumouris sof  
t,greyish brown.The  characteristic histologic feature is  the presence of 
Schiller –Duval body.  
 
Figure 13 a: shows histology of yolk sac tumour 
 
             
Figure 13 b: shows schiller duval body 
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SEX CORD STROMAL TUMOURS  
 
FEMINIZING TUMOUR 
GRANULOSA CELL TUMOUR: 
 It contains cells that resembles granulosa cell of the graffian follicle.It 
constitutes 10% of malignant tumours.80% of women >40yrs while 5% of 
prepubertal girls. (Berek JS et al, 1995).  It presents with precocious 
puberty in prepubertal girls with the development of secondary sexual 
characters.In adult life it presents with hyperestrogenic features.In 
postmenopausal women it presents with postmenopausal bleeding. 
 
 It is an oval shaped tumour with soft consistency.Cut surface is 
reticular or trabeculated with areas of internal haemorrhage. The outer 
surface is smooth and lobulated. 
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 The cells are arranged either in cords or in trabeculae,surrounded by 
hyaline tissue.It contains Call-exner bodies.  
 
 
 
 
Figure 14:shows call exner bodies 
 
THECA CELL TUMOUR: 
This tumour  is always unilateral. Cut surface is yellow in colour.The 
tumour consists of spindle shaped cells with luteinization of cells.Figure 14 
b:shows histology shows spindle cells with luteinization  
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DIAGNOSIS 
 Ovarian tumour can be diagnosed from history,clinical examination 
and diagnostic modalities.History which include menstrual 
complaints,abdominal pain,other vague symptoms,any family history of 
malignancy and also any adnexal mass removal,marital and obstetric 
history. clinical examination include examination of supraclavicular nodes, 
palpation of Breast,presence of ascitis,adnexal mass evaluation by 
pervaginal and per rectal examination.  
 Diagnostic modalities  to confirm ovarian tumours include: 
 ULTRASONOGRAPHY 
 
 CA125 
 
 CT ABDOMEN AND PELVIS 
 
 COLOUR DOPPLER ULTRASONOGRAPHY 
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ULTRASONOGRAPHY 
      IAN DONALD (Father of obstetric ultrasound)  of University of 
Glasgow first used  ultrasonography, for monitoring  pregnancy . In the 
1950's, he used ultrasonography to  diagnose ovarian cyst . Three large 
studies concluded that transvaginal ultrasonography is the best modality for 
screening with  90% sensitivity   for stage I disease with a PPV of 7.4–
9.9%. 11 
       Van Nagell et al.48 screened 25,327 women using Transvaginal 
ultrasonography in asymptomatic women aged 50 years or over and women 
aged 25 years or over who had a family history of ovarian cancer.4 They 
reported a sensitivity of 85% for all stages of disease with a specificity of 
98.7% and a PPV of 14%. In addition, they reported  that with annual 
Transvaginal screening they could  able to detect the disease at stage I and  
stage II . 
      It identifies the site of origin of ovarian tumours,associated pathologies 
and ascites. It also  aids in differentiating malignant and benign ovarian 
tumours.conventional ultrasonography is widely used in the diagnosis of 
ovarian masses by the morphological pattern of the tumors but it  lacks 
specificity in distinguishing benign from malignant lesions.28 
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FEATURES OF BENIGN TUMOURS 
 
 Cyst size <8 cm in premenopausal,<5 cm in postmenopausal women 
 Thin wall 
 smooth inner wall structure  
 Anechogenicity of the lesions.  
 
 
             Figure 16 a.shows benign cystic  tumour 
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FEATURES OF MALIGNANT TUMOURS 
The sonographic finding of malignancy are  
 Multilocularity 
 Complex(solid/cystic) 
 Bilaterality 
 Thickness of cyst wall>3mm 
 Septal thickness>2mm 
 Papillary excrescences 
 Ovarian volume>10cm3 
 Presence of solid materials 
 Metastasis  
  Presence of ascitis  
 
 
 
 
 
 
 
Figure 16 b.  Shows malignant cystic tumour with internal echoes 
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 Complex mass have indistinct inner wall structure and solid  
components. Solid tumours   contains highly echogenic mass .They tend to 
be more often malignant(51.7%) . 
 
 If more than 80% has solid areas, they will be classified as solid and 
they carry risk of malignancy of 40% or more. Several researchers have 
distinguished the conditions, especially using pelvic ultrasound based on 
their morphological appearance  like 
(Sassone et al., 401991; Lerner et al., 1994 24;  Valentin, 1999a ; 1999b 47; 
Ferrazzi et al, 200511). 
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CT ABDOMEN AND PELVIS: 
          Computed tomography (CT) was  introduced  30 years back into 
clinical practice . CT is widely used for the diagnosis of ovarian cancer for 
diagnosing the primary disease, for staging, monitoring response to 
treatment and diagnosis of recurrent disease. 
             Conventional CT scanners are made with a tube that generates  a 
narrow x-ray beam that passes through the patient ,which is picked up by a 
row of detectors on the other side. The tube and detectors are positioned on 
the opposite sides of a ring and rotate around the patient. The incorporation 
of slip ring technology into the design of scanners in the late 1980s enables 
the tube to rotate in a single direction indefinitely (spiral or helical CT). 
         The  time  of scan is very  much shorter.  In many studies ,CT has a 
sensitivity of 59% to 63% and specificity of 81% to 83%.The false-negative 
predictive value is 37% to 41%, whereas the false-positive predictive value 
is 17% to 19%. 
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CT is superior to other modalities in diagnosing: 
 Lobulated solid mass 
 
  Lymph node metastases 
 
 Involvement of the omentum 
 
 Presence or absence of ascites 
 
 Involvement of the liver 
 
 
 
 
 
Figure 17.shows bilateral stage 1 b malignant tumour 
The major disadvantage of CT scanners is the amount of radiation 
exposure to the patient. CT scan  which involves  a series of x-rays, which 
build  up a three-dimensional picture of the inside of the body. It takes 10–
30 minutes and it is painless. It has considerable amount of radiation hazard.  
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TUMOUR MARKERS 
                 Tumour markers are substances that are identified in higher 
amounts in blood ,urine and body tissues of patients with specific 
malignancy.CA125 is a Glycoprotein used for screening  and diagnosis of 
epithelial tumours of ovary. It is the antigenic determinant recognized by a 
monoclonal antibody of CA125 is a mucin (MUC 16) of more than 1M Da 
with an intracellular, trans membrane and extracellular domain. 
               The extracellular domain is heavily glycosylated and consists of 
multiple repeating subunits with 154 amino acids. A protease cleavage site 
is found in the extracellular domain. CA125 was first detected using the 
OC125 murine monoclonal antibody 2. 
             It is also used for monitoring  of patients on chemotherapy and for 
follow up.It may also raised in other conditions like pelvic inflammatory 
disease ,endometriosis, peritonitis and in  some malignant conditions like 
carcinoma breast,colon,lung and endometrium.Itmay be raised in 1%  
normal women. 
 
 
 
values >35U/L  is significant 
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A number of factors are known to influence serum CA125 levels in 
healthywomen like age(premenopausal women have higher levels of CA125 
than postmenopausal women),menstrual cycle(Some women have 
fluctuating serum CA125 levels throughout the menstrual 
cycle),pregnancy(CA125 increase during pregnancy),race(significantly 
higher CA125 are found in healthy causacian women compared to asian or 
african women).These factors should be taken into account when 
interpreting CA125 test results.   
 It is  also used for follow up after surgery,when level increases it 
indicates residual tumour.CA125 increased in only 50% of stage1 ovarian 
tumour and 90% in stage 2 ovarian tumour.22Specificity of CA125 can be 
combined with transvaginal ultrasonography.Serum CA-125 is one of the 
most useful tumor markerin differentiating  benign and malignant ovarian 
cancer.2,21,22However, the positive and negative predictive valuesof this 
marker are generally low9,24 
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COLOUR DOPPLER 
Doppler was first described by CHRISTIAN ANDREAS 
DOPPLER in 1842 who described the Doppler Principle.  
In 1955, Ultrasonic medical applications of this principle were 
applied by Shigeo Satomura and Yasuhara Nimura for observing blood 
flow.The technology used in this system  relies on the fundamental piezo-
electric crystal technology found by the Pierre Curie.  
The origin to the modern diagnostic ultrasound technique is based on 
the  works of Chilowsky and Langavin   SONAR (sound navigation and 
ranging) published in 1916, which was the first successful application of 
ultrasound.When ultrasound pulses are  directed into a medium, it causes the 
particle in the medium to vibrate parallel to the direction of wave 
propagation, this process of transmitted vibration from particle to particle 
lead to propagation of ultrasound through medium.  
 Three possible interactions take place 
 Reflection: Reflection occurs at the interface between two dissimilar 
medium. It is dependent on the tissues acoustic impedance and the 
beam’s angle of incidence. 
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 Refraction: Binding of waves as they pass from one medium to 
another is called refraction can cause artifacts. Refraction artifacts 
cause spatial distortion and loss of resolution in the image. 
 Absorption: Energy is dissipated, in the form of heat. 
Ultrasound wave is generated by the piezoelectric crystals lead zirconate 
titanate in the transducer .As the sound pulse passes through the patient 
body it interact with tissue in accordance with the characteristics of targeted 
tissue. The results of these interactions are recorded for diagnosis in the 
form of ultrasound wave incident on a transducer.  
The reflected waves are received by the transducer, these waves carry 
energy and they transmit the energy to the crystal elements. This 
compression forces the tiny dipole to change their orientation, which 
induces a voltage between the electrodes. The voltage is amplified and 
serves as the ultrasonic signal for display on an oscilloscope or television 
monitor. 
The physical component of probe include, the Handle (the part held by 
operator), the Shaft(portion which enters the vagina),Tip, head or 
footprint(which houses the US crystal).most Transvaginal probes uses 
frequency in the range of 5 to 7.5 MHz. scan angle may vary from 90 to 115 
degree scanning angles. 
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BIOLOGICAL EFFECT OF ULTRASOUND 
Physical effects of ultrasound can be divided into two groups 
1. Thermal 
2. Non-thermal 
THERMAL EFFECTS 
Ultrasound produces heat through the attenuation of sound as it 
passes through tissues, which in turn causes loss of penetration and inability 
to image deeper tissues. Factors controlling tissue heating include 
 Spatial focusing 
 Frequency of ultrasound 
 Duration of exposure 
 Tissue type. 
NON THERMAL EFFECTS 
Non thermal mechanisms can result in application of radiation forces 
(non-ionizing) both at microscopic and macroscopic level resulting in 
exerted pressure and torque. Acoustic fields can also cause induced motion 
to flow of fluids known as streaming. 
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Acoustic cavitation is action of fields which generates bubbles which 
undergoes volume pulsation and collapse in response to acoustic field.  
Other results of this activity are free radicle generation, microstreaming 
around bubble and mechanical action from bubble collapse.  
SAFTEY CONSIDERATIONS: 
 It seems overall thermal considerations do not adversely affect the 
safety in pulse echo scanning while for Doppler ultrasound the caution that 
needs to be exercised is that examination should be kept as short as possible. 
Methods to minimize the harmful effects: 
      Effects can by  minimized by 
1. Setting machine on default output settings. 
2. Keeping the time for which transducer is in contact to minimum. 
3. Keep acoustic output at the minimum consistent with good results. 
            The general consensus as stated by American institute of ultra 
sound in medicine (AIUM) bio effects committee is that “no confirmed 
biological effects on patients or instrument operators caused by exposure at 
intensities typical of present diagnostic ultrasound instruments have ever 
been reported. Where ever possible the principle of ALARA (as low as 
reasonably achievable) should be practiced. 
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                        DOPPLER PRINCIPLE 
The sound waves whether perceived as low or high frequency will 
depend upon whether the sound source moving towards or away from the 
listener.the amount of this frequency shift is directly proportional to velocity 
of sound source.thus frequency shift between ultrasound transducer and 
echoes returning from Red blood cell are noted. 
 Blood flow velocity  is directionaly proportional to blood pressure 
and is Inversely proportional to vascular resistance. sampling point on the 
line of the pulsed Doppler beamwas positioned where the colored dots 
within the tumor.This  placement of the beam revealed the presence of 
vessels and these positions were followed  and captured. 
CONTINUOUS WAVE TRANSDUCER 
Continuous transducer consists of a transmitter that continuously emits 
sound and a receiver continuously receives frequency shift. It doesnot 
discriminate echoes according to their depth. 
PULSE WAVE TRANSDUCER 
It emits ultrasound for a fraction of a second and then switch over to 
the receiver mode. This  provide depth discrimination by echo delay time. 
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          Echoes that are returning from specified tissue are measured.doppler 
gate or sample volume which are selected depth are positioned within the 
vessel lumen.Aquired signal fron specific anatomical location noted 
           An advanced variation of color Doppler is power Doppler and is 
found to have a better diagnostic potential than conventional Doppler 24. 
Power Doppler measures the energy of a returning Doppler signal rather 
than analyzing the flow pattern. An advantage of power Doppler is that it 
can evaluate low-velocity blood flow. A further improvement of power 
Doppler is 3D power Doppler, providing imaging and measurement of 
blood flow in solid areas and excrescences of complex cysts 25 
                       Cohen et al. studied 71 women with solid and complex ovarian 
masses to evaluate if 3D power Doppler was superior to 2D power Doppler 
in evaluating ovarian masses. They found that all malignancies were 
correctly identified by both 2D and 3D imaging; however, the specificity 
significantly improved with the addition of 3D power Doppler . Availability 
of the instruments and the necessary expertise for interpretation has limited 
the use of both techniques. 
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           Doppler waveforms (Bourne et al.,4 1989; Hata et al.17,1989; Kurjak 
et al 1991.,23Kurjak et al.,1993 25)reports showed the superiority of this 
technique in screening ovarian cancer. (Bourne et al., 1989; Kurjak etal., 
1991) reported the ability of the colour Doppler in differentiating benign 
from malignant tumors preoperative.  
            This was  proposed by Kurjak et al(1993c). When no blood flow 
was detectable within the tumor,signal placed on  peripheral areas  of the 
tumour or theadnexal branch of the ovarian artery .Both pulsatility index 
(PI) and resistance index (RI)were calculated. The value of each artery was 
calculatedfrom a curve fitted to the average waveform over three cardiac 
cycles. 
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INTERPRETATION OF COLOUR DOPPLER 
 A colour Doppler system not only find frequency shift but also the 
direction of flow encoded by colour coding system 
 
RED- Towards the transducer 
BLUE- Away from the transducer 
 
 
 
 
 
 
 
 
 
 
 
         Figure 18 a.shows  colour Doppler of benign tumour with less vascularity 
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Figure 18 b .shows colour Doppler image of malignant tumour with increased flow 
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Several angle independent indices are noted to analyse frequency shift 
1.S/D ratio of STUART 
2.Formula used for  calculating RI 
Resistive index of POURCELOT: 
 
 
RI = (S-D)/S 
 
3.The formulas used for PI  
 PI-Pulsality index 
                          
PI = (S-D)/mean 
 
 
S - Maximum Doppler frequency shift in Systole 
 D – Minimum Doppler frequency shift in Diastole 
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              Signals from various areas within the tumor were determined but 
the lowest PI and RI were considered for data analysis.Furthermore, the area 
distribution of visualized vesselsin the adnexal masses was also categorized 
and recorded as  in the center of the mass, in the septum, in the papillae, at 
peri-tumour areas.
 
figure 18 c.shows Doppler waveforms of ovarian vessels. 
 Malignant neoplasm offer low resistance  to blood flow due to 
presence of aberrant tumour vessels. 
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RESISTIVE INDEX 
Cutoff values  
BENIGN >0.4 
MALIGNANT <0.4 
                               Table no 1a:cut off values of RI 
 
           Cutoff values used by most of researches for RI 
STUDY CUT OFF VALUE 
Kurjak et al 0.4 
Timor-tritsch et al 0.4 
Zanetta et al 0.56 
              Table 1b:cut values of RI in other studies 
 
 In previous studies, some authors suggested the existence of clear cut-
off points of PI and RI of benign and malignant tumours. Kurjak et al 
(1991) 25 reported only one false positive and two false negative results in 
study population of 624 benign ovarian tumors and 56 malignant tumors by 
using a cut-off value of RI-0.4. 
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          Timor-Tritsch et al (1993)  45 explained that RI value of 0.4 had 
sensitivity 93.8% and specificity of 98.7% which was different from the 
studyof Zanetta et al(1994).51 Who used the cut off value of RI as 0.56. 
                                  PULSALITY INDEX 
Cutoff values 
BENIGN >1 
MALIGNANT <1 
                                 Table 2a:cutoff value of PI 
STUDY  CUTOFF VALUES 
Sengoku et al 1.5 
Theeratongsong 1.2 
Weiner et al 1.0 
Table 2b: cut off values  of PI in other studies 
 
 Sengoku et al (1994)  42concluded sensitivity and specificity of 
81.3% and 91.7% respectively when the cutoff value of PI 1.5. Study done 
by  Theera tong song  46 reported  that, among 306 patients  191 are benign 
and 115 aremalignant.sensitivity and specificity of RI is 93% and 
92.7%respectively.sensitivity and specificity of PI is 94.8% and 
93.2%respectively. 
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Among 306 cases, the mean PI values of tumour arteries were 1.73 , 
0.97  and 0.88 for benign tumor, low malignant potential tumor and cancer, 
respectively. When cancer and low malignant potential tumors are 
considered together, their mean PI was 0.89. The mean PI in the benign and 
malignant group was significantly different (Student’s T test, p<0.001). 
 
Based on receiver-operating characteristics (ROC) curve  area best 
cut-off Value PI was 1.20, which gave sensitivity and specificity of 93.0% 
and92.7%,  respectively ,with area under curve of 0.960  with 
95%Confidence interval. The mean RI values were 0.81 , 0.50 and 0.44  for 
benign tumor, low malignant potential tumor and cancer, respectively. The 
mean RI was 0.45  if malignant and Borderline tumors were considered 
together. The mean RI in the benign and malignant group was significantly 
different(Student’s Ttest, p<0.001). Based on receiver-operating 
characteristics(ROC) curve with area under curve of 0.95 with (95% 
Confidence interval), the best cut-off RI was 0.62, which gave  
sensitivity and specificity of 94.8% and 93.2%, respectively  
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AIMS AND OBJECTIVE OF THE STUDY 
 To study the accuracy, sensitivity and specificity of Colour Doppler 
in diagnosing Benign and Malignant ovarian tumours in 15-60 yrs age 
group patients attending Gynaecology Clinic at Government Kilpauk 
Medical College Hospital, Chennai. 
 To study the incidence of age group in which the malignancy is most 
common. 
INCLUSION CRITERIA 
 All women diagnosed to have significant 
 adnexal mass (size > 5 cm) between 15 to 60 years. 
EXCLUSION CRITERIA 
 Known case of ovarian tumour came for second look surgery 
 Anechoic unilocular cyst <5 cm in ovary that resolves on follow up  
 Endometriotic cyst which likely to give false positive results. 
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MATERIALS AND METHODS 
Ethical Committee 
Ethical committee clearance obtained in January 2012. 
Study Design 
Prospective observational study 
Place of Study 
 Gynaecology Outpatient Department at  Kilpauk Medical 
College,Chennai. 
      Duration of study-January 2012 –September 2013 
Sample size-75 calculated by the formula 
Sample Size for Frequency in a Population 
Population size(for finite population correction factor or fpc)(N): 250  
Hypothesized % frequency of outcome factor in the population (p):  7%+/-5  
Confidence limits as % of 100(absolute +/- %)(d): 5% 
Design effect (for cluster surveys-DEFF): 1   
 
Sample Size(n) for Various Confidence Levels  
 
 Confidence  Level(%) Sample Size   
 95%  72   
Equation  
Sample size n = [DEFF*Np(1-p)]/ [(d2/Z21-α/2*(N-1)+p*(1-p)]  
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METHODS OF COLLECTION OF DATA 
               All ovarian tumour cases posted for surgery were selected and data 
obtained by complete history starting from presenting complaints,  history 
of presenting illness, obstetric history, menstrual history, past history of 
adnexal mass removal, family history of malignancy,  clinical  examination  
including complete gynaecological examination   done . 
             All routine investigations done with specific investigations like 
Ultrasonography,  CT abdomen and pelvis,CA125 and Colour Doppler done 
calculating resistive and pulsality index. Findings are noted intraoperatively. 
Finally results were comparedwith  Histopathology[HPE] 
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STATISTICAL ANALYSIS: 
 
Chart:1 
TOTAL INCIDENCE OF BENIGN AND MALIGNANT  CASES 
AMONG 75 SAMPLE SIZE 
 
This chart  shows the distribution of benign and malignant tumours 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
BENIGN MALIGNANT
80%
20%
TOTAL CASES DISTRIBUTION
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Table:3.2 
pearson chi square value 3.443 
P value(Asymp.sig.2-sided) 0.064 
Computed by 2*2 table.significant at <0.05 
  
CORRELATION OF AGE WISE DISTRIBUTION  AND HPE 
TABLE  NO:3.1 
   HPE  
   BENIGN MALIGNANT Total 
AGE GROUP 15-40yrs Count 36 5 41 
% within HPE 60.0% 33.3% 54.7% 
% of Total 48.0% 6.7% 54.7% 
41-60yrs Count 24 10 34 
% within HPE 40.0% 66.7% 45.3% 
% of Total 32.0% 13.3% 45.3% 
 Total Count 60 15 75 
% within HPE 100.0% 100.0% 100.0% 
% of Total 80.0% 20.0% 100.0% 
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Pie Chart: 1 
 
 
33% is malignant in age group 15-40yrs,whereas 67%  is malignant in  
41-60yrs  age group. 
From the above data, It is found that malignancy is most common in the age 
group of 41-60yrs. 
From table no 3.2  ,p value -0.064,which is statistically not significant. 
 
41-60YRS
67%
15-40YRS
33%
AGE WISE DISTRIBUTION OF MALIGNANT 
TUMOURS
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BAR CHART :1
 
Barchart showing Distribution of age groups in benign and malignant 
tumour 
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CORRELATION OF MENOPAUSAL AGE WITH HPE 
Table :4.1cross table 
   HPE  
   BENIGN MALIGNANT Total 
PRE 
MENOPAUSAL 
AGE 
POST 
MENOPAUSAL 
AGE 
 
 
 
 
Count 49 8 57 
% within HPE 81.7% 53.3% 76.0% 
% of Total 65.3% 10.7% 76.0% 
 Count 11 7 18 
% within HPE 18.3% 46.7% 24.0% 
% of Total 14.7% 9.3% 24.0% 
 Total Count 60 15 75 
% within HPE 100.0% 100.0% 100.0% 
% of Total 80.0% 20.0% 100.0% 
 
Table:4.2 
Pearson chi square value 5.281 
Asym sig.(2-sided) 0.022 
Kappa value 0.464 
Computed by 2*2 table.significant at <0.05 
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PIECHART 2 
 
From table no:4.1  
It is clear that  among malignancy 8(53.3%) are premenopausal      and 7 
(46.7%)are postmenopausal.P value -0.022,which is statistically not 
significant.Kappa value -0.464, which has moderate significance. 
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BAR CHART:2
 
Bar Chart showing association of postmenopausal age with malignancy 
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CORRELATION OF HISTORY OF MALIGNANCY WITH 
HISTOPATHOLOGY 
Table :5.1 Cross tab 
 
   HPE  
   Benign Malignant Total 
 No 
H/O Malignancy 
Count 60 7 67 
% within HPE 100% 46.6% 89.3% 
% of Total 80.0% 9.3% 89.3% 
H/o 
Malignancy 
Count 0 8 8 
% within HPE 0% 53.3% 10.7% 
% of Total 0% 10.7% 10.7% 
 Total Count 60 15 75 
% within HPE 100.0% 100.0% 100.0% 
% of Total 80.0% 20.0% 100.0% 
Table :5.2 
Pearson chi square value 5.222 
P value (2 sided sig) 0.024 
Computed by 2*2 table.significant at <0.05 
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Pie Chart:3 
 
From table no:5,it is noted that 8 among 15 malignant patients have history 
of malignancy constituting about 53.3% . 
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BAR CHART:3 
 
Barchart showing association of H/o Malignancy with malignant 
tumours  
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CORRELATION RESULTS OF ULTRASOUND  WITH 
HISTOPATHOLOGY 
Table:6.1Crosstab 
   HPE  
   Benign Malignant Total 
USG Benign Count 49 5 54 
% within 
HPE 
81.7% 33.3% 72.0% 
% of Total 65.3% 6.7% 72.0% 
Malignant Count 11 10 21 
% within 
HPE 
18.3% 66.7% 28.0% 
% of Total 14.7% 13.3% 28.0% 
 Total Count 60 15 75 
% within 
HPE 
100.0% 100.0% 100.0% 
% of Total 80.0% 20.0% 100.0% 
      
 
 
 
Table :6.2 
 
Kappa 0.420 
App sig. .000 
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BAR CHART:5      USG WITH HPE
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RESULTS OF ULTRASONOGRAPHY 
 
Table:6.3 
Sensitivity 66.67% 
Specificity 81.67% 
Positive likelihood value 3.64 
Negative Likelihood Ratio 0.41 
Disease prevalence 20% 
Positive Predictive Value 47.62% 
Negative Predictive Value 90.74% 
Table 5: shows ultrasound results 
Hence the sensitivity of ultrasonography is 66.7% And specificity is 82%. 
Kappa is 0.420 which is statistically significant 
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CORRELATION OF CT ABDOMEN AND PELVIS RESULTS WITH 
HISTOPATHOLOGY 
Table:7.1 
Crosstab 
   HPE  
   0 1 Total 
CT 0 Count 51 3 54 
% within HPE 85.0% 20.0% 72.0% 
% of Total 68.0% 4.0% 72.0% 
1 Count 9 12 21 
% within HPE 15.0% 80.0% 28.0% 
% of Total 12.0% 16.0% 28.0% 
 Total Count 60 15 75 
% within HPE 100.0% 100.0% 100.0% 
% of Total 80.0% 20.0% 100.0% 
      
It diagnose 85% of benign tumour and 80% of malignant tumours. 
Table:7.2 
Kappa value 0.565 
App.sig 0.000 
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 BAR CHART:5 
 
This bar chart correlate the  CT with HPE 
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RESULTS OF CT ABDOMEN AND PELVIS 
Table:7.3 
Sensitivity 80.00% 
Specificity 85.00% 
Positive Likelihood Ratio 5.33 
Negative Likelihood Ratio 0.24 
Disease prevalence 20.00% 
Positive Predictive Value 57.14% 
Negative Predictive Value 94.44% 
 
                            
 
 
From the above study, it is noted that the sensitivity and specificity of 
ultrasonography is 80% and 85% respectively.kappa value –0.565 which 
has moderate significance. 
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CORRELATION OF CA125 RESULTS WITH  HISTOPATHOLOGY 
Table:8.1 
Crosstab 
   HPE  
   0 1 Total 
CA125 0 Count 50 5 55 
% within HPE 83.3% 33.3% 73.3% 
% of Total 66.7% 6.7% 73.3% 
1 Count 10 10 20 
% within HPE 16.7% 66.7% 26.7% 
% of Total 13.3% 13.3% 26.7% 
 Total Count 60 15 75 
% within HPE 100.0% 100.0% 100.0% 
% of Total 80.0% 20.0% 100.0% 
 
From table no: 8.1  83.3% of benign tumours and  66.7% of malignant 
tumours are diagnosed by CA 125  
Table:8.2 
kappa value 0.444 
App.sig 0.000 
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BAR CHART:6 
 
This bar chart correlates findings of CA125 and HPE 
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RESULTS OF CA125 
Table:8.3 
Sensitivity 66.67% 
Specificity 83.33% 
Positive Likelihood Ratio 4 
Negative Likelihood Ratio 0.40 
Disease prevalence 20% 
Positive Predictive Value 50% 
Negative Predictive Value 
 
90.91% 
Table : 8.3-shows results of CA125 
 
CA125 diagnosed 50 patients as benign  among 60  benign tumours and 10 
patients as malignant in 15 malignant tumours.Kappa value is 0.444 which 
has moderate significance.from the above data,Sensitivity of  CA125 is 
66.67% and specificity is 83.33%. 
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INTERPRETATION OF DOPPLER  RESULTS 
ROC CURVE  FOR RESISTIVE  INDEX 
 
Sensitivity of resistive index when the cut off value is 0.5  gives the 
sensitivity and specificity is 93.3% and 86.7% respectively. 
Area under curve is 0.922 which is statistically significant p value-<0.0001 
 
 
 
DOPPLER RI
0 20 40 60 80 100
0
20
40
60
80
100
100-Specificity
S
en
si
tiv
ity
 Sensitivity: 93.3
 Specificity: 86.7
 Criterion : ≤0.5
 
 
76 
 
Area under the ROC curve (AUC)  of RESISTIVE INDEX 
Table:9.1 
 Cut off value 0.5 
Area under curve 0.922 
Standard Error 0.0609 
Significant level(Area=0.5) <0.0001 
  
 
 
Area under curve is 0.922 which is statistically significant  
 
p value-<0.0001. 
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  RECEIVER OPERATING CURVE FOR PULSALITY INDEX 
 
With the PI of 0.9 the sensitivity and specificity is 86.7 %and 93.3%  
respectively 
Area under curve is 0.925  which is statistically significant p value<0.0001 
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 Area under the ROC curve (AUC)  of PULSALITY INDEX 
Table:9.2 
Cut off value for PI 0.9 
Area  under the ROC curve (AUC 0.925 
Standard Error 0.0413 
Significance level P (Area=0.5 <0.0001 
 
Area under curve is 0.925 which is statistically significant  
 
p value <0.0001 
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INTERPRETATION OF DOPPLER WITH HISTOPATHOLOGY 
TABLE :10.1 
 
   HPE  
   Benign Malignant Total 
DOPPL
ER 
Benig
n 
Count 56 1 57 
% within 
HPE 
93.3% 6.7% 76.0% 
% of Total 74.7% 1.3% 76.0% 
Malig
nant 
Count 4 14 18 
% within 
HPE 
6.7% 93.3% 24.0% 
% of Total 5.3% 18.7% 24.0% 
 Total Count 60 15 75 
% within 
HPE 
100.0% 100.0% 100.0% 
% of Total 80.0% 20.0% 100.0% 
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Bar chart: 7 
 
DIAGNOSED NOT DIAGNOSED
56 4
DIAGNOSIS BY DOPPLER IN BENIGN 
TUMOURS
 
 
81 
 
Barchart: 8 
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Table 10.2 
kappa measure of agreement  0.806 
  Mcnemar chi-square test 
(Exact sig-2 sided) 
 
0.375 
                                                        N 75 
 
This bar chart correlates Doppler detection of malignancy with HPE
 
Doppler accurately  diagnosed  93.3% of benign tumours  and 93.3% of 
malignant tumours. 
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RESULTS OF DOPPLER    
 
Sensitivity 93.33%   
Specificity 93.33%   
Positive Predictive Value 77.78%   
Negative Predictive Value 98.25%   
Diagnostic Accuracy 93.33%   
 
from the above data,with taking RI and PI together the sensitivity  and 
specificity of colour Doppler 93.3%and 93.3% respectively.Diagnostic 
accuracy of colour Doppler is 93.3%. 
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DISCUSSION 
 The diagnosis of malignant ovarian tumours are utmost important to 
decrease the mortality and morbidity of patients. Hence the aim of the study 
is to evaluate the accuracy of colour Doppler in diagnosing benign and 
malignant ovarian tumours against gold standard histopathology.  
 The present study included a study group of 75 patients,who were 
planned for surgery were selected and all diagnostic modalities were done. 
Colour Doppler ultrasound done and resistive and pulsality index were 
calculated . Results was compared with the histopathology. We didn’t get  
any case of fallopian tube mass. 
 The results were compared with the other studies which were already 
performed and discussed as follows. 
 
                                              Out of 75 cases  
                                    
                  MALIGNANT(15 )                 ( 60) BENIGN 
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Age group in which the malignancy is most common are studied. 
Epithelial ovarian cancers are most common in women who are over 50 
years of age, and who are post-menopausal. Study done by national cancer 
intelligence network in 2009 reported that Epithelial tumours are the most 
common morphological group of ovarian cancer,  accounting for 32% of all 
cases in 2009, and is particularly common in women aged 45-74 at 
diagnosis.  Borderline accounting for 14% of cases and is most common in 
women aged under 45. Sex cord-stromal or germ cell tumours are most 
common in women under the age of 35, particularly in girls and young 
women in their 20’s. 
Our study reported that 60% of Benign tumours are more common in 
age group of 15-40yrs and 66.7% of Malignant tumours are common in age 
group of 41-60yrs. In malignant tumours epithelial tumours are more 
common in 41-60yrs and germ Cell tumours are common in 20-30yrs.  
 In most of the studies conducted by kurjak et al 23,25,lancet et al 
described that malignancy is most common in  postmenopausal womens.our 
study reported that 7 out of 15 malignancy patients constituting about 
46.7%  are postmenopausal. 
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      Women with family history of ovarian cancer  in the mother and sister 
have 3 to 4 times the risk of ovarian cancer  than women without a family 
history. Our study reported that 8 among the 15 malignant patients 
constituting 53.3%, have history of malignancy either in the mother, sister 
or close relatives. 
     Conventional ultrasonography is widely used in diagnosis of ovarian 
masses by the morphological pattern of the tumors but  it lacks sensitivity in 
distinguishing benign from malignant lesions.1 Van Nagell et al 49. screened 
25,327 women using Transvaginal ultrasonography , reported a sensitivity 
of 85% for all stages of disease with a specificity of 98.7% and a PPV of 
14%. 
     In our study the Sensitivity  and  specificity of ultrasonography is 67% 
and 82% respectively.To conclude , ultrasound have low specificity and 
sensitivity compared to  colour Doppler study. 
     Studies conducted by kitajima k,senda k  in 2011 reported that 
sensitivity, specificity and accuracy of CT scanning to detect malignant or 
borderline tumors were 82.4, 76.9, and 81.1%, respectively. 
In our study ,CT abdomen and pelvis have sensitivity  of  80 %  and  
specificity of  85% . 
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     The Shizuoka Cohort Study of  Ovarian Cancer Screening randomly 
assigned  women and studied role of CA125 reported the sensitivity of 56 
%and  specificity of 93%in stage 1 disease.in advanced stage it is 73 %and 
94.4% respectively. 
     In our study CA 125  has  got sensitivity of 66.7% and  specificity of 
83.3% Kurjak 25and colleague reported  that resistance index less than 0.4 
was highly sensitive and specific in predicting ovarian malignancy . Using 
regression analysis, both Tailor and coworkers and Schelling and 
associates have found that colour Doppler have high sensitivity and 
specificity in diagnosing malignant tumours. 
     Timor-Tritsch et al (1993)  45 reported the RI value of 0.4 had sensitivity 
93.8% and specificity of 98.7% . Considering RI value of 0.5 as the cut-off 
point,  in our study the sensitivity and specificity are 93.3%and 86.7% 
respectively. 
     Cut-off  level of PI value 0.9, giving the sensitivity and specificity of  
86.7%and 93.3% respectively, was similar to the study of Sengoku et al 
(1994)   42  reported sensitivity and specificity of 81.3% and 91.7% 
respectively. 
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      Study conducted by Theeretongsong  46 in march 2008 found that 
among 306 cases 191 were benign and 115 were malignant.The sensitivity 
and specificity of the  resistive index were 94.8 % and 93.2%  respectively  
with the cut off value of 0.4 and the values for pulsatility index  were 93.0% 
and 92.7% with the cut off value of 1.2. 
      The summary of research by  receiver  operating characteristic (SROC) 
methodology first described by Moses et al. 29 and  Irwig et al 19 was 
applied. 
     Area under curve for RI is 0.922  if the cut off value is <0.5with the 95% 
confidence interval.And the p value is <0.0001. 
     AArea under curve for PI is 0.945 if the cut off value is <0.9 with the 
95% confidence interval.and the p value is <.0001 
METHODS USED IN STATISTICS 
The accuracy of the test depends on how well the test separates the 
group being tested into those with and without the disease in question. 
Accuracy is measured by the area under the ROC curve. An area of 1 
represents a perfect test; an area of .5 represents a worthless test. A rough 
guide for classifying the accuracy of a diagnostic test is the traditional 
academic point system:  
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ROC CURVE 
 .90-1 = excellent (A)  
 .80-.90 = good (B)  
 .70-.80 = fair (C)  
 .60-.70 = poor (D)  
 .50-.60 = fail (F) 
 
KAPPA  AGREEMENT.  
Creates a classification table, from raw data in the spreadsheet, for two 
observers and calculates an inter-rater agreement statistic (Kappa) to 
evaluate the agreement between two classifications on ordinal or nominal 
scales (Cohen, 1960; Fleiss et al., 2003). 
 
Value of K Strength of agreement  
< 0.20 Poor 
0.21 - 0.40 Fair 
0.41 - 0.60 Moderate 
0.61 - 0.80 Good 
0.81 - 1.00 Very good 
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SUMMARY 
 
This study concludes that colour Doppler has more sensitivity and 
specificity in differentiating benign and malignant tumours when compared 
to other diagnostic modalities. 
 
This study also reveals that 
 
 Benign tumours are most common in 15-40 yrs and malignant 
tumours are most common  in 41-60 yrs. 
 Epithelial tumours are most common in postmenopausal patients 
about 70%.Germ cell tumours are common in premenopausal 
patients. 
 Family history of malignancy correlate  well with the malignancy 
rate. 
 Ultrasonography has sensitivity and specificity 66.7% and 81% 
respectively 
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  CT Abdomen and pelvis has sensitivity and specificity of 80% and 
85% respectively 
 
 Ca125 has sensitivity and specificity of 66.67% and 83.3%  
Respectively 
 
 Resistive index has sensitivity and specificity of 93.3% and 
specificity of 86.7% respectively 
 
 Pulsality  Index has sensitivity and specificity of 86% and 94% 
respectively 
 
 
  With considering both RI and PI the Doppler has  sensitivity and 
specificity are 93.3% and 93% respectively. 
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CONCLUSION 
 Ovarian tumours are most common malignant tumour among 
gynaecological cancer.ovarian cancer is a hidden form of gynaecological 
malignancy  which usually reveales itself in a stage where the spread has 
occured extensively. 
 
         Early detection and prompt treatment is very important. Early 
diagnosis will increase the survival rate of the  cancer patients.33 Use of 
colour Doppler sonography as a diagnostic and as a screening tool for 
ovarian cancer is the best choice recommended.This study substantiates and 
confirms this recommendation. 
 
         Its being a non invasive diagnostic modality it can be easily performed 
without much difficulty without causing discomfort to patients.Increasing 
availability of colour Doppler along with ultrasonography at reasonable 
costs has made it affordable  even to the poor socioeconomic status. 
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0 0 0.8 0 1.3 0 0 
SEROUS 
CYSTADENOMA 
0 0   
36 
Meenat
chi 
3
2 
131
039
0 
0 0 0 0 
12.
7 
0 0 0.7 0 1.4 0 0 
MUCINOUS 
CYSTADENOMA 
0 1   
37 Ammu 
5
0 
130
987
6 
1 0 0 0 38 1 0 0.8 0 1.1 0 0 KERATOTIC CYST 0 3   
38 Jayanthi 
3
2 
130
298
4 
0 0 0 0 
12.
1 
0 0 0.8 0 1.2 0 0 DERMOID CYST 0 2   
39 
Saraswa
thi 
5
7 
131
456
7 
1 0 0 1 
56.
8 
1 1 0.3 1 0.7 1 1 
MUCINOUS 
CYSTADENOCARCIN
OMA 
1   1 
40 Bargath 
4
1 
132
455
6 
1 0 1 0 
3.5
6 
0 0 0.7 0 1.3 0 0 
MUCINOUS 
CYSTADENOMA 
0 1   
41 Shanthi 
3
9 
132
413
4 
0 0 0 0 7.8 0 0 0.8 0 1.2 0 0 DERMOID CYST 0 2   
            
 
 
42 muthayi 
4
1 
132
456
6 
1 0 0 0 4.5 0 0 0.5 0 1.3 0 0 
SEROUS 
CYSTADENOMA 
0 0   
43 
Umapra
kash 
4
0 
130
299
3 
0 0 0 0 
23.
4 
0 0 1.3 0 1.3 0 0 
SEROUS 
CYSTADENOMA 
0 0   
44 Vinitha 
3
2 
132
009
9 
0 0 1 0 8.9 0 0 0.9 0 1.4 0 0 
MUCINOUS 
CYSTADENOMA 
0 1   
45 
Rebecc
a 
3
9 
131
889
2 
0 0 0 0 
10.
2 
0 0 0.8 0 1.1 0 0 DERMOID CYST 0 2   
46 
vasanth
ammal 
4
2 
132
366
7 
1 0 0 0 
64.
7 
1 1 0.5 0 1 0 1 
IMMATURE 
TERATOMA 
1   4 
47 
Rajeswa
ri 
4
0 
131
245
6 
0 0 0 0 
32.
6 
0 0 0.8 0 1.2 0 0 
SEROUS 
CYSTADENOMA 
0 0   
48 
Mahes
wari 
3
4 
132
569
0 
0 1 1 0 
31.
5 
0 0 0.9 0 1.3 0 0 
SEROUS 
CYSTADENOMA 
0 0   
49 
Yogalak
shmi 
2
3 
131
245
6 
0 0 0 1 
56.
8 
1 1 0.5 0 0.7 1 1 
MUCINOUS 
CYSTADENOCARCIN
OMA 
1   1 
50 Abitha 
1
9 
131
245
5 
0 0 1 0 
32.
6 
0 0 0.9 0 1.2 0 0 
MUCINOUS 
CYSTADENOMA 
0 1   
51 Amul 
4
8 
132
445
5 
1 0 0 0 
23.
6 
0 0 0.7 0 1.4 0 0 
SEROUS 
CYSTADENOMA 
0 0   
52 Janaki 
2
8 
131
458
9 
0 0 0 0 
45.
6 
1 1 1.2 0 1.3 0 0 DYSGERMINOMA 1   2 
53 
Nazree
n 
4
6 
131
890
9 
0 1 0 1 57 1 1 0.3 1 0.4 1 1 
SEROUS 
CYSTADENOCARCIN
OMA 
1   0 
54 
pitchai
muthu 
3
0 
132
456
3 
0 0 1 0 32 0 0 0.8 0 1.5 0 0 
SEROUS 
CYSTADENOMA 
0 0   
55 
Panjava
rnam 
4
6 
132
459
0 
1 0 0 1 
37.
9 
1 1 0.7 0 1 0 0 
MUCINOUS 
CYSTADENOMA 
0 1   
56 Ranjani 
3
2 
133
278
9 
0 0 0 0 24 0 0 0.9 0 1.2 0 0 
SEROUS 
CYSTADENOMA 
0 0   
            
 
 
57 
kunjam
ma 
4
8 
133
389
0 
1 1 0 1 
12.
4 
0 1 0.1 1 0.6 1 1 
SEROUS 
CYSTADENOCARNO
MA 
1   0 
58 Uma 
3
0 
131
245
6 
0 0 0 0 
30.
8 
0 0 0.6 0 1.3 0 0 
SEROUS 
CYSTADENOMA 
0 0   
59 
petchia
mmal 
4
6 
133
234
5 
1 0 0 0 
23.
5 
0 0 0.9 0 1.2 0 0 FOLLICULAR CYST 0 4   
60 Mallika 
4
1 
133
425
6 
1 0 0 0 
18.
5 
0 0 0.9 0 1.3 0 0 DERMOID CYST 0 2   
61 Vimala 
3
2 
132
455
5 
0 1 0 1 13 0 0 0.4 1 0.5 1 1 
MUCINOUS 
CYSTADENOMA 
0 1   
62 
Rajeswa
ri 
5
1 
131
222
2 
1 0 0 0 
14.
6 
0 0 0.8 0 1.2 0 0 
SEROUS 
CYSTADENOMA 
0 0   
63 Selvi 
3
8 
132
345
6 
0 0 0 0 8.9 0 0 0.8 0 1.3 0 0 
SEROUS 
CYSTADENOMA 
0 0   
64 
Dowlat
h 
5
1 
132
489
1 
1 1 0 0 
76.
8 
1 1 0.4 1 0.3 1 1 
SEROUS 
CYSTADENOCARCIN
OMA 
1   0 
65 
Palania
mmal 
4
3 
132
467
8 
1 0 0 0 
3.5
6 
0 0 0.8 0 1.3 0 0 
MUCINOUS 
CYSTADENOMA 
0 1   
66 Radhika 
2
1 
132
444
4 
0 0 0 1 
67.
8 
0 0 1.2 0 1.4 0 0 DERMOID CYST 0 2   
67 
Subhath
ara 
4
7 
133
245
6 
1 1 0 0 
12.
3 
0 0 0.4 1 0.6 1 1 
MUCINOUS 
CYSTADENOCARCIN
OMA 
1   1 
68 
vasanth
i 
2
7 
133
125
6 
0 0 0 0 3.4 0 1 0.9 0 1.2 0 0 
SEROUS 
CYSTADENOMA 
0 0   
69 
Durgad
evi 
3
6 
133
332
4 
0 0 0 0 
32.
4 
0 0 0.8 0 1.4 0 0 DERMOID CYST 0 2   
70 
Muthul
akshmi 
3
2 
133
456
7 
0 0 0 0 
12.
9 
0 1 1.1 0 1.4 0 0 
SEROUS 
CYSTADENOMA 
0 0   
71 
Visalatc
hi 
3
4 
133
245
6 
0 0 0 0 
13.
5 
0 0 1.2 0 1.3 0 0 DERMOID CYST 0 2   
            
 
 
72 
Kaliam
mal 
4
3 
132
678
9 
1 1 0 1 
35.
6 
1 1 0.3 1 0.7 1 1 
GRANULOSA CELL 
TUMOUR 
1   3 
73 
ponna
mal 
3
5 
133
420
8 
0 0 0 0 
25.
6 
0 0 0.9 0 1.3 0 0 
SEROUS 
CYSTADENOMA 
0 0   
74 prema 
3
2 
133
245
6 
0 0 0 0 
23.
45 
0 0 0.8 0 1.1 0 0 
MUCINOUS 
CYSTADENOMA 
0 1   
75 ambika 
3
2 
133
211
2 
0 0 0 0 8.9 0 0 0.7 0 1 0 0 
SEROUS 
CYSTADENOMA 
0 0   
                        0               
 
            
 
 
KEY TO MASTER CHART: 
0-BENIGN 
1-MALIGNANT 
HPE-HISTOPATHOLOGY 
RI-RESISTIVE INDEX 
PI-PULSALITYINDEX 
 
 
IN     “R” COLUMN,BENIGN TUMOURS 
 
0-SEROUS CYSTADENOMA 
1-MUCINOUS CYSTADENOMA 
2-DERMOID 
3-KERATOTIC CYST 
4-FOLLICULAR CYST 
 
IN  “S” COLUMN ,MALIGNANT TUMOURS 
 
0-SEROUS CYATAEDNOCARCINOMA 
1-MUCINOUS CYST ADENOCARCINOMA 
2-DYSGERMINOMA 
3-GRANULOSA CELL TUMOUR 
4-MATURE TERATOMA 
 
            
 
 
 
